SERES THERAPEUTICS INC. - COMMON STOCK

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

16 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

09 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

16 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

09 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

22 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

13 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

06 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

30 сен 2024 17:15:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

26 сен 2024 16:01:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

13 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

12 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

13 авг 2024 07:00:01 Источник Nasdaq GlobeNewswire

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

06 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

06 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 июн 2024 16:00:00 Источник Nasdaq GlobeNewswire

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

06 июн 2024 06:30:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: SERES THERAPEUTICS INC. - COMMON STOCK

19 апр 2024 09:45:04 Источник NetDania Notify

NetDania - New 12 months Low: SERES THERAPEUTICS INC. - COMMON STOCK

18 апр 2024 13:43:28 Источник NetDania Notify

NetDania - New 12 months Low: SERES THERAPEUTICS INC. - COMMON STOCK

17 апр 2024 11:09:31 Источник NetDania Notify

NetDania - New 12 months Low: SERES THERAPEUTICS INC. - COMMON STOCK

16 апр 2024 09:49:29 Источник NetDania Notify